Stay updated on PF-06439535 vs Bevacizumab in NSCLC Clinical Trial
Sign up to get notified when there's something new on the PF-06439535 vs Bevacizumab in NSCLC Clinical Trial page.

Latest updates to the PF-06439535 vs Bevacizumab in NSCLC Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedRevision: v3.6.3 is now shown, replacing v3.6.0. This reflects a backend update to the site rather than changes to the study details.SummaryDifference0.0%

- Check34 days agoChange DetectedNew help and navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and the Intervention/Treatment label; recruitment status now states 'No longer looking for participants', and the page revision is updated to v3.6.0.SummaryDifference0.1%

- Check41 days agoChange DetectedRevision updated the page version from v3.5.4 to v3.5.5. This reflects a small update to the page without changing the study details or other visible content.SummaryDifference0.0%

- Check63 days agoChange DetectedThe revision tag on the page was updated from v3.5.3 to v3.5.4, replacing the previous version indicator. This reflects a minor update to the page's version history without altering visible content.SummaryDifference0.0%

- Check85 days agoChange DetectedThe page revision/version indicator was updated from v3.5.2 to v3.5.3, reflecting a site release rather than any change to the underlying clinical trial information.SummaryDifference0.0%

- Check92 days agoChange DetectedAdded Valparaiso and Araucania locations, including Temuco, Araucania, Chile (4810469) and Viña del Mar, Valparaiso, Chile (2540364). Removed Temuco, Región de la Araucanía, Chile (4810469) and Viña del Mar, Región de Valparaíso, Chile (2540364); revision updated from v3.5.0 to v3.5.2.SummaryDifference0.2%

Stay in the know with updates to PF-06439535 vs Bevacizumab in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the PF-06439535 vs Bevacizumab in NSCLC Clinical Trial page.